Total Payments
$2,700
2024 Payments
$357.57
Companies
26
Transactions
101
Medicare Patients
4,324
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$2,649 (98.1%)
Education$51.78 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,649 | 100 | 98.1% |
| Education | $51.78 | 1 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $888.97 | 32 | $0 (2024) |
| CSL Behring | $282.23 | 11 | $0 (2024) |
| Lilly USA, LLC | $206.79 | 10 | $0 (2024) |
| UCB, Inc. | $176.85 | 7 | $0 (2023) |
| Shire North American Group Inc | $119.88 | 1 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $114.67 | 4 | $0 (2021) |
| Lundbeck LLC | $114.07 | 4 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $106.60 | 4 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $97.57 | 3 | $0 (2023) |
| Biogen, Inc. | $62.86 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $357.57 | 13 | CSL Behring ($104.73) |
| 2023 | $676.74 | 25 | UCB, Inc. ($176.85) |
| 2022 | $141.48 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($41.64) |
| 2021 | $160.30 | 7 | Alexion Pharmaceuticals, Inc. ($64.46) |
| 2020 | $103.71 | 5 | CSL Behring ($24.23) |
| 2019 | $446.52 | 25 | ACADIA Pharmaceuticals Inc ($121.85) |
| 2018 | $235.83 | 14 | ACADIA Pharmaceuticals Inc ($207.38) |
| 2017 | $578.20 | 5 | ACADIA Pharmaceuticals Inc ($458.32) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $40.04 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Neuroscience | ||||||
| 11/04/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $26.54 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/30/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Neurology | ||||||
| 10/21/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $36.13 | General |
| Category: Immunology | ||||||
| 09/24/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Neuroscience | ||||||
| 09/17/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $31.07 | General |
| Category: Neurology | ||||||
| 09/10/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: AMANTADINE | ||||||
| 08/22/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $29.65 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/21/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Neuroscience | ||||||
| 05/09/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $29.81 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/04/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: AMANTADINE | ||||||
| 03/26/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $28.56 | General |
| Category: Immunology | ||||||
| 12/11/2023 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: Immunology | ||||||
| 11/29/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug), Ongentys | Food and Beverage | In-kind items and services | $33.35 | General |
| Category: Neuropsychiatry | ||||||
| 10/24/2023 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Immunology | ||||||
| 10/17/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/16/2023 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Neuroscience | ||||||
| 10/10/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $49.36 | General |
| 10/04/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $30.64 | General |
| Category: PSYCHIATRY | ||||||
| 09/18/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $33.92 | General |
| Category: PSYCHIATRY | ||||||
| 09/12/2023 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Neuroscience | ||||||
| 09/07/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $33.73 | General |
| 09/06/2023 | Neurocrine Biosciences, Inc. | Ongentys (Drug), INGREZZA | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: Neuropsychiatry | ||||||
| 08/31/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $21.66 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 974 | 3,540 | $1.6M | $291,588 |
| 2022 | 15 | 873 | 3,247 | $1.5M | $275,075 |
| 2021 | 17 | 1,139 | 3,577 | $1.8M | $317,071 |
| 2020 | 19 | 1,338 | 3,593 | $2.0M | $325,954 |
Total Patients
4,324
Total Services
13,957
Medicare Billing
$1.2M
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 189 | 759 | $474,362 | $79,537 | 16.8% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2023 | 19 | 598 | $275,080 | $63,772 | 23.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 205 | 934 | $304,484 | $53,291 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 158 | 301 | $260,640 | $45,115 | 17.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 75 | 394 | $59,888 | $10,813 | 18.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 28 | 28 | $55,692 | $10,177 | 18.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 48 | 48 | $50,640 | $8,589 | 17.0% |
| 90869 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent motor threshold redetermination with delivery and management | Office | 2023 | 18 | 21 | $19,047 | $3,792 | 19.9% |
| 90785 | Psychiatric services complicated by communication factor | Office | 2023 | 108 | 299 | $20,930 | $3,723 | 17.8% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2023 | 19 | 19 | $15,086 | $3,662 | 24.3% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 14 | 39 | $16,107 | $2,946 | 18.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 23 | 28 | $17,018 | $2,880 | 16.9% |
| 95930 | Measurement of nerve conduction using visual stimulation testing with report | Office | 2023 | 27 | 27 | $9,180 | $1,680 | 18.3% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 27 | 27 | $5,054 | $875.34 | 17.3% |
| 99423 | Online digital evaluation and management service for an established patient for up to 7 days, total time 21 or more minutes | Office | 2023 | 16 | 18 | $4,032 | $737.64 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 203 | 731 | $464,122 | $77,715 | 16.7% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 22 | 631 | $339,372 | $66,573 | 19.6% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 184 | 842 | $280,386 | $49,074 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 138 | 264 | $230,733 | $40,148 | 17.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 30 | 31 | $61,628 | $11,259 | 18.3% |
| 90853 | Group psychotherapy | Office | 2022 | 16 | 283 | $36,224 | $5,999 | 16.6% |
| 99358 | Extended patient service without direct patient contact, first hour | Office | 2022 | 38 | 47 | $24,393 | $4,230 | 17.3% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 18 | 20 | $20,942 | $3,857 | 18.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 23 | 23 | $25,064 | $3,735 | 14.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 28 | 34 | $15,820 | $3,351 | 21.2% |
About Dr. David Merrill, MD
Dr. David Merrill, MD is a Psychiatry healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1902923410.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Merrill, MD has received a total of $2,700 in payments from pharmaceutical and medical device companies, with $357.57 received in 2024. These payments were reported across 101 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($2,649).
As a Medicare-enrolled provider, Merrill has provided services to 4,324 Medicare beneficiaries, totaling 13,957 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Los Angeles, CA
- Active Since 03/22/2007
- Last Updated 07/18/2024
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1902923410
Products in Payments
- NUPLAZID (Drug) $888.97
- Hizentra (Biological) $282.23
- REXULTI (Drug) $173.80
- AMYVID (Drug) $160.12
- MYDAYIS (Drug) $119.88
- SPRAVATO (Drug) $95.70
- Soliris (Drug) $64.46
- Ongentys (Drug) $64.22
- VYVGART HYTRULO (Drug) $55.97
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $49.46
- Gocovri (Drug) $49.11
- ONPATTRO (Drug) $47.71
- KISUNLA (Drug) $46.67
- Quicktome (Device) $46.29
- ADUHELM (Biological) $42.28
- SOLIRIS (Drug) $42.14
- GAMMAGARD (Biological) $41.64
- INGREZZA (Drug) $33.35
- INFINITY (Device) $28.55
- NUEDEXTA (Drug) $26.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Los Angeles
Dr. Walter Ling, Md, MD
Psychiatry — Payments: $397,562
Psychiatry $397,562
Dr. Jakub Juros, Md, MD
Psychiatry — Payments: $363,152
Psychiatry $363,152
Lon Schneider, Md, MD
Psychiatry — Payments: $270,419
Psychiatry $270,419
John Brooks, M.d, M.D
Psychiatry — Payments: $134,275
Psychiatry $134,275
Stephen Marder, Md, MD
Psychiatry — Payments: $119,068
Psychiatry $119,068
Alexander Bystritsky
Psychiatry — Payments: $55,320
Psychiatry $55,320